Study of Icatibant in Idiopathic Angioedema

• Research type

  Research Study

• Full title

  Open label, single-centre study to evaluate the efficacy of the bradykinin (BK) B2 receptor antagonist, Icatibant, in the relief of symptoms resulting from moderate to severe angioedema unresponsive to antihistamines

• IRAS ID

  84476

• Contact name

  Hilary Longhurst

• Sponsor organisation

  Barts and the London NHS Trust

• Eudract number

  2011-002339-24

• ISRCTN Number

  NA

• Clinicaltrials.gov Identifier

  NA

• Research summary

  The study is looking to assess the efficacy of the bradykinin (BK) B2 antagonist, Icatibant (study drug), in the relief of symptoms resulting from moderate to severe angioedema (swelling) of the face, neck, areas, genitals, tongue, pharynx and larynx, where the diagnosis is of Idiopathic Angioedema - unresponsive to Antihistamines. Currently treatment of this drug is licensed for Hereditary Angioedema (HAE) which is thought to be caused by the bradykinin pathways. It is felt (from clinical evidence and research to date) that this medication (study drug/Icatibant) and can be successful in the treatment of Idiopathic Angioedema.

• REC name

  London - Riverside Research Ethics Committee

• REC reference

  11/LO/1941

• Date of REC Opinion

  12 Jan 2012

• REC opinion

  Further Information Favourable Opinion